FilingSEC EDGAR6-K
NovaBridge Subsidiary Visara Enters License Agreement for VIS-102 Ophthalmology Therapy
· SEC accepted
StageClinical Stage
Filing content
Visara secured exclusive worldwide rights, excluding Greater China, to develop and commercialize VIS-102 for neurotrophic keratitis from Wuhan Hiteck. The agreement includes a $7 million upfront payment plus potential milestone payments and royalties.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…